A study reveals that when Dna2 is absent, small DNA fragments jump from all over the genome into chromosome breaks. This novel mechanism may explain similar events commonly seen in cancer or during antibody diversification.
A team of researchers shows Food and Drug Administration (FDA)-approved compounds can stop cancer growth and can potentially lead to the discovery of drugs in a way that is quicker and less expensive than traditional drug development strategies.
Dr. Tao Wu recently joined the Department of Molecular and Human Genetics at Baylor College of Medicine as an assistant professor through a $2 million recruitment grant from the Cancer Prevention and Research Institute of Texas (CPRIT).
In a recent study, researchers combined clinical and laboratory studies to show the PPM1D gene can confer blood cells exposed to the chemotherapy agent cisplatin a survival advantage that might favor the development of leukemia years later.
Dr. Alastair Thompson is bringing his expertise Baylor as the new section chief of breast surgery in the Michael E. DeBakey Department of Surgery, Division of Surgical Oncology, and co-director of the Lester and Sue Smith Breast Center.
A team of physician-scientists at Baylor College of Medicine and Texas Children’s Hospital are now using a new treatment option for pediatric patients with liver tumors, called Transarterial Radioembolization (TARE).
The National Cancer Institute has awarded $6.3 million dollars Baylor researchers to create new tools to help researchers to better understand the biological causes behind racial and ethnic health disparities in prostate and breast cancers.
To better understand a predisposition for acute lymphoblastic leukemia in children with Down syndrome, a team of researchers will sequence the genomes of more than 2,000 individuals with Down syndrome.
In a review published in New England Journal of Medicine, physician-scientists review the history of Langerhans-cell histiocytosis (LCH) and the recent developments that will help propel the treatment for patients into the realm of personalized medicine.
To establish a better understanding of the link between the risk for liver cancer and non-alcoholic fatty liver disease (NAFLD), researchers conducted a large, retrospective study of patients with and without NAFLD.